K
Karu Jayathilake
Researcher at Vanderbilt University
Publications - 48
Citations - 3005
Karu Jayathilake is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Atypical antipsychotic & Schizophrenia. The author has an hindex of 21, co-authored 44 publications receiving 2810 citations. Previous affiliations of Karu Jayathilake include Veterans Health Administration & Hacettepe University.
Papers
More filters
Journal ArticleDOI
H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs
Wesley K. Kroeze,Sandra J. Hufeisen,Beth A. Popadak,Sean Michael Renock,Seanna Steinberg,Paul Ernsberger,Karu Jayathilake,Herbert Y. Meltzer,Bryan L. Roth +8 more
TL;DR: It is recommended that the next generation of atypical antipsychotic drugs be screened to avoid H1-histamine receptors, which are known to induce weight gain with chronic use.
Journal ArticleDOI
A genome-wide investigation of SNPs and CNVs in schizophrenia
Anna C. Need,Dongliang Ge,Michael E. Weale,Jessica M. Maia,Sheng Feng,Erin L. Heinzen,Kevin V. Shianna,Woohyun Yoon,Dalia Kasperavičiūtė,Massimo Gennarelli,Warren J. Strittmatter,Cristian Bonvicini,Giuseppe Rossi,Karu Jayathilake,Philip A. Cola,Joseph P. McEvoy,Richard S.E. Keefe,Elizabeth M. C. Fisher,Pamela L. St. Jean,Ina Giegling,Annette M. Hartmann,Hans-Jürgen Möller,Andreas Ruppert,Gillian Fraser,Caroline Crombie,Lefkos T. Middleton,David St Clair,Allen D. Roses,Pierandrea Muglia,Clyde Francks,Dan Rujescu,Herbert Y. Meltzer,David Goldstein +32 more
TL;DR: These data suggest that very few schizophrenia patients share identical genomic causation, potentially complicating efforts to personalize treatment regimens and support the emerging view that rare deleterious variants may be more important in schizophrenia predisposition than common polymorphisms.
Journal ArticleDOI
Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior.
TL;DR: It is suggested that hopelessness, substance abuse, greater insight into illness, and higher cognitive function are associated with greater suicidality in chronic schizophrenia, but that among these, hopelessness may be the principal predictor of suicIDality.
Journal ArticleDOI
Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment
Tomiki Sumiyoshi,Mie Matsui,Shigeru Nohara,Ikiko Yamashita,Masayoshi Kurachi,Chika Sumiyoshi,Karu Jayathilake,Herbert Y. Meltzer +7 more
TL;DR: The results suggest the usefulness of 5-HT(1A) agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia.
Journal ArticleDOI
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
A. Elif Anıl Yağcıoğlu,Berna Binnur Akdede,Tolga I Turgut,Mevhibe Tumuklu,M. Kâzım Yazıcı,Köksal Alptekin,Aygun Ertugrul,Karu Jayathilake,A. Gögüs,Zeliha Tunca,Herbert Y. Meltzer +10 more
TL;DR: Adjunctive risperidone treatment in schizophrenia patients partially responsive to clozapine does not significantly improve psychopathology or quality of life compared to placebo in a 6-week period.